|
|
|
|
|
|
|
26.02.26 - 12:48
|
New GLP1 pill helps patients lose up to 8% of body weight, trial shows (The Guardian)
|
|
|
Daily orforglipron tablets led to greater weight loss than semaglutide tablets, offering potential oral alternative to Wegovy and MounjaroA new daily pill could be a more effective GLP-1 tablet for weight loss, according to a clinical trial that may pave the way for a non-injection alternative to Wegovy and Mounjaro.The drug, called orforglipron and manufactured by Eli Lilly, is prescribed for type 2 diabetes and targets the same GLP-1 receptors as oral semaglutide. Like semaglutide, it lowers blood sugar levels, slows digestion and suppresses appetite. However, unlike semaglutide tablets, it does not need to be taken on an empty stomach. Continue reading......
|
|
|
|
|
|
|
25.02.26 - 18:48
|
Eli Lilly Aktie: Warum Novos GLP-1-Schritt laut BofA wenig ändert (Aktiencheck)
|
|
|
Charlotte (www.aktiencheck.de) - Eli Lilly-Aktienanalyse von BofA Securities:
Die Analysten von BofA Securities stufen die Aktie von Eli Lilly and Company (ISIN: US5324571083, WKN: 858560, Ticker-Symbol: LLY, NYSE-Symbol: LLY) weiterhin mit "buy" ein.
Die heutige Ankündigung von Novo Nordisk (NVO), die Listenpreise für GLP-1-Präparate zu senken, sorge zwar für eine aufmerksamkeitsstarke Schlagzeile, habe nach Einschätzung von BofA jedoch voraussichtlich keine wesentlichen Auswirkungen auf den US-Markt. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.02.26 - 18:06
|
Novo Nordisk setzt Eli Lilly unter Druck (Der Aktionaer)
|
|
|
Im frühen US-Handel zählen die Anteilscheine von Eli Lilly zu den schwächsten Titeln. Denn der dänische Rivale Novo Nordisk plant deutliche Preissenkungen für seine Blockbuster-Medikamente in den USA. Wie Führungskräfte dem Wall Street Journal mitteilten, sollen ab Januar 2027 die Preise für das Abnehmpräparat Wegovy und das Diabetesmittel Ozempic gesenkt werden....
|
|
|
|
|
24.02.26 - 15:39
|
Novo Nordisk Extends Slide After Announcing Price-Cuts For Blockbuster Obesity Drugs (ZeroHedge)
|
|
|
Novo Nordisk Extends Slide After Announcing Price-Cuts For Blockbuster Obesity Drugs
Novo Nordisk shares in Copenhagen can't catch a bid. The liquidation is accelerating again after a Bloomberg headline on Tuesday morning: the Danish drugmaker will slash U.S. list prices for Wegovy and Ozempic next year. The move suggests that the new CEO is pursuing market share amid intensifying competition in the GLP-1 space.
Jamey Millar, Novo's head of U.S. operations, was quoted by Bloomberg as saying the company set a monthly price of $675 for its family of semaglutide drugs, a reduction of up to 50%. The new pricing regime is set to take effect on Jan. 1, 2027.
Millar said Novo had to announce the new cuts now to allow time to adjust ahead of next year's rollout.
Meanwhile, Zepbound, Eli Lilly's competing obesity drug, currently has a list price of around $1,086.
Bloomberg pointed out: "The price drop will apply to the wholesale acquisition cost, a published price that doesn't reflect the com...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
